{"protocolSection":{"identificationModule":{"nctId":"NCT01436162","orgStudyIdInfo":{"id":"SPD489-323"},"secondaryIdInfos":[{"id":"2011-003006-25","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Takeda","class":"INDUSTRY"},"briefTitle":"Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder","officialTitle":"The SPD489-323 Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Inadequate Response to Prospective Treatment With an Antidepressant"},"statusModule":{"statusVerifiedDate":"2021-05","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2011-10-19","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2013-12-10","type":"ACTUAL"},"completionDateStruct":{"date":"2013-12-10","type":"ACTUAL"},"studyFirstSubmitDate":"2011-09-15","studyFirstSubmitQcDate":"2011-09-16","studyFirstPostDateStruct":{"date":"2011-09-19","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-10-31","resultsFirstSubmitQcDate":"2014-11-06","resultsFirstPostDateStruct":{"date":"2014-11-07","type":"ESTIMATED"},"dispFirstSubmitDate":"2014-08-20","dispFirstSubmitQcDate":"2014-08-20","dispFirstPostDateStruct":{"date":"2014-08-22","type":"ESTIMATED"},"lastUpdateSubmitDate":"2021-05-25","lastUpdatePostDateStruct":{"date":"2021-06-09","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Shire","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms. Eligible patients will remain on their antidepressant but will be randomized to either receive supplemental SPD489 or placebo (i.e. sugar pill). The purpose of this study is to help answer the following questions:\n\n* How safe is SPD489 for the supplemental treatment of depression and what are the side effects that might be related to it?\n* Can supplemental SPD489 help patients who still have residual depression symptoms while taking an antidepressant?\n* How much SPD489 should be given to patients with depression who are also taking an antidepressant?\n* How does SPD489 compare to placebo in depressed patients who are also taking an antidepressant?"},"conditionsModule":{"conditions":["Major Depressive Disorder"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":1105,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Antidepressant + SPD489","type":"EXPERIMENTAL","interventionNames":["Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate )"]},{"label":"Antidepressant + Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Antidepressant + Placebo"]}],"interventions":[{"type":"DRUG","name":"Antidepressant + SPD489 (Lisdexamfetamine dimesylate )","description":"Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + SPD489 (oral, 20, 30, 50 or 70 mg, once daily) for 8 weeks","armGroupLabels":["Antidepressant + SPD489"],"otherNames":["Vyvanse"]},{"type":"DRUG","name":"Antidepressant + Placebo","description":"Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks","armGroupLabels":["Antidepressant + Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at 8 Weeks","description":"MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.","timeFrame":"8 weeks"}],"secondaryOutcomes":[{"measure":"Mean Change From Baseline in Sheehan Disability Scale (SDS) Total Score at 8 Weeks","description":"Designed to evaluate the extent to which illness symptoms impact a subject's life in 3 areas: work/school, social, and family/home. Each area is scored on a scale from 0 (no impairment) to 10 (highly impaired) with a total score ranging from 0 (unimpaired) to 30 (highly impaired). Lower scores translate into less impairment.","timeFrame":"8 weeks"},{"measure":"Percentage of Participants Achieving a 25% Response on the MADRS","description":"The percentage of subjects who achieved a 25% response (i.e. ≥25% reduction in MADRS total score from the Lead-in Baseline, Visit 2).","timeFrame":"Up to 8 weeks"},{"measure":"Percentage of Participants Achieving a 50% Response on the MADRS","description":"The percentage of subjects who achieved a 50% response (i.e. ≥50% reduction in MADRS total score from the Lead-in Baseline, Visit 2).","timeFrame":"Up to 8 weeks"},{"measure":"Percent of Participants Achieving Remission on the MADRS","description":"MADRS remission was defined as a MADRS total score of ≤10.","timeFrame":"Up to 8 weeks"},{"measure":"Mean Change From Baseline Over Time in MADRS Total Score","description":"MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.","timeFrame":"Up to 8 weeks"},{"measure":"Mean Change From Baseline in Abbreviated Brief Assessment of Cognition Affective Disorders (ABAC-A) Composite T-Scores","description":"The ABAC-A is a rater-administered series of activities designed to be sensitive to the critical cognitive deficits in affective disorders and schizophrenia. There are 6 subtests of the ABAC-A: List Learning (verbal memory); Digit Sequencing Task (working memory); Token Motor Task (motor speed); Verbal Fluency; Symbol Coding (attention and processing speed); and Tower of London Test (executive functions). The ABAC-A Composite T-score change from Augmentation Baseline Visit (Visit 8; Week 8) at Visit 14/Early Termination (ET) (Week 16/ET) was analyzed.","timeFrame":"up to 8 weeks"},{"measure":"Mean Change From Baseline in the Short Form-12 Health Survey V2 (SF-12V2)","description":"Total score ranges from 0 (lowest level of health) - 100 (highest level of health) on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability (i.e. a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability). Higher scores are associated with better quality of life.","timeFrame":"Up to 8 weeks"},{"measure":"Mean Change in Sexual Functioning Questionnaire - 14 Item Scale (CSFQ-14) Total Score Male","description":"The CSFQ-14 is a short-form interview/questionnaire that measures illness- and medication-related changes in sexual functioning. A 5-point Likert scale is used ranging from 1 (never) to 5 (always). The CSFQ-14 total score can range from 14 to 70, with lower scores being associated with worsened sexual functioning.","timeFrame":"Up to 8 weeks"},{"measure":"Mean Change in Sexual Functioning Questionnaire - 14 Item Scale (CSFQ-14) Total Score Female","description":"The CSFQ-14 is a short-form interview/questionnaire that measures illness- and medication-related changes in sexual functioning. A 5-point Likert scale is used ranging from 1 (never) to 5 (always). The CSFQ-14 total score can range from 14 to 70, with lower scores being associated with worsened sexual functioning.","timeFrame":"Up to 8 weeks"},{"measure":"Clinical Global Impressions - Global Improvement (CGI-I)","description":"Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.","timeFrame":"Up to 8 weeks"},{"measure":"Mean Change From Baseline in the Multidimensional Assessment of Fatigue (MAF) Global Fatigue Index (GFI)","description":"MAF contains 16 items scored on a scale from 1 (not at all) to 10 (a great deal). Answers are converted to a Global Fatigue Index with total scores ranging from 1 (no fatigue) to 50 (severe fatigue). Lower scores indicate less fatigue.","timeFrame":"Up to 8 weeks"},{"measure":"Columbia Suicide Severity Rating Scale (C-SSRS)","description":"C-SSRS is a semi-structured interview that captures the occurence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale.","timeFrame":"Up to 8 weeks"},{"measure":"Amphetamine Cessation Symptom Assessment (ACSA) - Total Aggregate Score","description":"ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity.","timeFrame":"8 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n1. Subject is able to provide written, personally signed, and dated informed consent to participate in the study before completing any study-related procedures.\n2. Subject is between 18 and 65 years of age.\n3. Subject has a primary diagnosis of non-psychotic MDD.\n4. Subject has a MADRS total score \\>/=24.\n5. Subject is willing and has an understanding and ability to fully comply with study procedures and restrictions defined in this protocol.\n6. Subject, who is female, must have a negative serum beta human chorionic gonadotropin (B-HCG) pregnancy test and a negative urine pregnancy test and agrees to comply with any applicable contraceptive requirements of the protocol.\n7. Subject is able to swallow a capsule.\n\nExclusion Criteria:\n\n1. Subject whose current episode of MDD has not responded to an adequate treatment regimen with 2 or more approved single antidepressant agents.\n2. Subject who has a lifetime history of treatment resistant depression, defined as having not responded to adequate treatment with 2 or more treatment regimens.\n3. Subject has a current co-morbid psychiatric disorder that is either controlled with medications prohibited in this study or is uncontrolled and associated with significant symptoms.\n4. Subject has been hospitalized (within the last 12 months) for their current MDD episode.\n5. Subject has a current or lifetime history of attention-deficit/hyperactivity disorder (ADHD).\n6. Subject has a first degree relative that has been diagnosed with bipolar I disorder.\n7. Subject has a recent history (within the last 6 months) of suspected substance abuse or dependence disorder.\n8. Subject is considered a suicide risk, has previously made a suicide attempt within the past 3 years, or is currently demonstrating active suicidal ideation.\n9. Subject has a concurrent chronic or acute illness or unstable medical condition.\n10. Subject has a history of seizures (other than infantile febrile seizures), any tic disorder, or a current diagnosis and/or a known family history of Tourette's Disorder, serious neurological disease, history of significant head trauma, dementia, cerebrovascular disease, Parkinson's disease, or intracranial lesions.\n11. Subject has known history of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems.\n12. Subject has a history of thyroid disorder that has not been stabilized on thyroid medication or treatment within 3 months prior to the Screening Visit.\n13. Subject has a known family history of sudden cardiac death or ventricular arrhythmia.\n14. Subject has glaucoma.\n15. Subject has any clinically significant ECG or clinical laboratory abnormalities.\n16. Subject has a history of moderate to severe hypertension.\n17. Current use of any other medications (including over-the-counter \\[OTC\\], herbal or homeopathic preparations) that have central nervous system effects.\n18. Subject has the potential need to initiate or modify frequency of psychotherapy or to continue or initiate other treatments for depression, outside of those allowed in this protocol.\n19. Subject has had electroconvulsive therapy (ECT) for the current depressive episode 3 months prior to the Lead-in Baseline Visit.\n20. The subject has a known or suspected intolerance or hypersensitivity to the investigational product.\n21. The subject has a known or suspected intolerance, hypersensitivity, or contraindications to their assigned antidepressant treatments (escitalopram oxalate, sertraline HCl, venlafaxine HCl extended release, or duloxetine HCl).\n22. Subject has a positive urine drug result.\n23. Subject has a body mass index (BMI) of \\<18.5 or \\>40.\n24. Subject is female and is pregnant or nursing.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Study Director","affiliation":"Takeda","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"ResearchOne, Inc.","city":"Scottsdale","state":"Arizona","zip":"85251","country":"United States","geoPoint":{"lat":33.50921,"lon":-111.89903}},{"facility":"K&S Professional Research Services, LLC","city":"Little Rock","state":"Arkansas","zip":"72201","country":"United States","geoPoint":{"lat":34.74648,"lon":-92.28959}},{"facility":"ATP Clinical Research, Inc.","city":"Costa Mesa","state":"California","zip":"92626","country":"United States","geoPoint":{"lat":33.64113,"lon":-117.91867}},{"facility":"Diligent Clinical Trials","city":"Downey","state":"California","zip":"90241","country":"United States","geoPoint":{"lat":33.94001,"lon":-118.13257}},{"facility":"Synergy Clinical Reserach Center of Escondido","city":"Escondido","state":"California","zip":"92025","country":"United States","geoPoint":{"lat":33.11921,"lon":-117.08642}},{"facility":"Pacific Research Partners, LLC","city":"Oakland","state":"California","zip":"94612","country":"United States","geoPoint":{"lat":37.80437,"lon":-122.2708}},{"facility":"Anderson Clinical Research","city":"Redlands","state":"California","zip":"92374","country":"United States","geoPoint":{"lat":34.05557,"lon":-117.18254}},{"facility":"BreakThrough Clinical Trials, LLC","city":"San Bernardino","state":"California","zip":"92408","country":"United States","geoPoint":{"lat":34.10834,"lon":-117.28977}},{"facility":"MCB Clinical Research Centers","city":"Colorado Springs","state":"Colorado","zip":"80910","country":"United States","geoPoint":{"lat":38.83388,"lon":-104.82136}},{"facility":"Florida Clinical Research Center, LLC","city":"Bradenton","state":"Florida","zip":"34201","country":"United States","geoPoint":{"lat":27.49893,"lon":-82.57482}},{"facility":"Scientific Clinical Research, Inc.","city":"North Miami","state":"Florida","zip":"33161","country":"United States","geoPoint":{"lat":25.89009,"lon":-80.18671}},{"facility":"Clinical Neuroscience Solutions, Inc.","city":"Orlando","state":"Florida","zip":"32806","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"Comprehensive NeuroScience, Inc.","city":"St. Petersburg","state":"Florida","zip":"33716","country":"United States","geoPoint":{"lat":27.77086,"lon":-82.67927}},{"facility":"Janus Center for Psychiatric Research","city":"West Palm Beach","state":"Florida","zip":"33407","country":"United States","geoPoint":{"lat":26.71534,"lon":-80.05337}},{"facility":"Atlanta Center for Medical Research","city":"Atlanta","state":"Georgia","zip":"30308","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Atlanta Institute of Medicine & Research","city":"Atlanta","state":"Georgia","zip":"30328","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Pedia Research","city":"Newburgh","state":"Indiana","zip":"47630","country":"United States","geoPoint":{"lat":37.94449,"lon":-87.40529}},{"facility":"Heartland Research Associates","city":"Wichita","state":"Kansas","zip":"67207","country":"United States","geoPoint":{"lat":37.69224,"lon":-97.33754}},{"facility":"Louisiana Clinical Research, LLC","city":"Shreveport","state":"Louisiana","zip":"71115","country":"United States","geoPoint":{"lat":32.52515,"lon":-93.75018}},{"facility":"Comprehensive Psychiatric Associates","city":"Gladstone","state":"Missouri","zip":"64118","country":"United States","geoPoint":{"lat":39.20389,"lon":-94.55468}},{"facility":"The Center for Pharmaceutical Research","city":"Kansas City","state":"Missouri","zip":"64114","country":"United States","geoPoint":{"lat":39.09973,"lon":-94.57857}},{"facility":"Mercy Health Research","city":"St Louis","state":"Missouri","zip":"63141","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Bio Behavioral Health","city":"Toms River","state":"New Jersey","zip":"08755","country":"United States","geoPoint":{"lat":39.95373,"lon":-74.19792}},{"facility":"Brooklyn Medical Institute","city":"Brooklyn","state":"New York","zip":"11214","country":"United States","geoPoint":{"lat":40.6501,"lon":-73.94958}},{"facility":"Medical & Behavioral Health Research, PC","city":"New York","state":"New York","zip":"10023","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Midwest Clinical Research Center","city":"Dayton","state":"Ohio","zip":"45417","country":"United States","geoPoint":{"lat":39.75895,"lon":-84.19161}},{"facility":"North Star Medical Research, LLC","city":"Middleburg Heights","state":"Ohio","zip":"44130","country":"United States","geoPoint":{"lat":41.36144,"lon":-81.81291}},{"facility":"Sooner Clinical Research","city":"Oklahoma City","state":"Oklahoma","zip":"73112","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"Lehigh Center for Clinical Research","city":"Allentown","state":"Pennsylvania","zip":"18104","country":"United States","geoPoint":{"lat":40.60843,"lon":-75.49018}},{"facility":"Belmont Center for Comprehensive Treatment","city":"Philadelphia","state":"Pennsylvania","zip":"19131","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"Medical University South Carolina Anxiety Disorder Program","city":"North Charleston","state":"South Carolina","zip":"29406","country":"United States","geoPoint":{"lat":32.85462,"lon":-79.97481}},{"facility":"Psychiatric Consultants, PC","city":"Franklin","state":"Tennessee","zip":"37067","country":"United States","geoPoint":{"lat":35.92506,"lon":-86.86889}},{"facility":"Research Strategies of Memphis, LLC","city":"Memphis","state":"Tennessee","zip":"38119","country":"United States","geoPoint":{"lat":35.14953,"lon":-90.04898}},{"facility":"KRK Medical Research","city":"Dallas","state":"Texas","zip":"75230","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Future Search Trials of Dallas, LP","city":"Dallas","state":"Texas","zip":"75231","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Clinical Trials of Texas, Inc.","city":"San Antonio","state":"Texas","zip":"78229","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"Dr Lieven De Weirdt","city":"Sint-Niklaas","zip":"9100","country":"Belgium","geoPoint":{"lat":51.16509,"lon":4.1437}},{"facility":"Saint Anne s.r.o.","city":"Brno","zip":"60200","country":"Czechia","geoPoint":{"lat":49.19522,"lon":16.60796}},{"facility":"Psychiatricka ambulance","city":"Brno","zip":"615 00","country":"Czechia","geoPoint":{"lat":49.19522,"lon":16.60796}},{"facility":"Medicana s.r.o.","city":"Hořovice","zip":"268 01","country":"Czechia","geoPoint":{"lat":49.83597,"lon":13.90268}},{"facility":"Psychiatrie s.r.o.","city":"Kutná Hora","zip":"284 01","country":"Czechia","geoPoint":{"lat":49.94839,"lon":15.26816}},{"facility":"Bialbi s.r.o.","city":"Litoměřice","zip":"41201","country":"Czechia","geoPoint":{"lat":50.53348,"lon":14.1318}},{"facility":"Clintrial s.r.o.","city":"Prague","zip":"10000","country":"Czechia","geoPoint":{"lat":50.08804,"lon":14.42076}},{"facility":"Psychiatry Trial s.r.o.","city":"Prague","zip":"15800","country":"Czechia","geoPoint":{"lat":50.08804,"lon":14.42076}},{"facility":"Prague Medical Services s.r.o.","city":"Prague","zip":"160 00","country":"Czechia","geoPoint":{"lat":50.08804,"lon":14.42076}},{"facility":"Ricany s.r.o.","city":"Říčany","zip":"251 01","country":"Czechia","geoPoint":{"lat":49.99168,"lon":14.65427}},{"facility":"Parnu Hospital, Psychiatric Clinic","city":"Pärnu","zip":"80012","country":"Estonia","geoPoint":{"lat":58.38588,"lon":24.49711}},{"facility":"North Estonia Medical Centre Foundation Psychiatry Clinic","city":"Tallinn","zip":"10614","country":"Estonia","geoPoint":{"lat":59.43696,"lon":24.75353}},{"facility":"Marienthal Psychiatry and Psychology Center","city":"Tallinn","zip":"10617","country":"Estonia","geoPoint":{"lat":59.43696,"lon":24.75353}},{"facility":"Jaanson & Laane OU","city":"Tartu","zip":"50406","country":"Estonia","geoPoint":{"lat":58.38062,"lon":26.72509}},{"facility":"Tartu University Hospital Psychiatric Clinic","city":"Tartu","zip":"50417","country":"Estonia","geoPoint":{"lat":58.38062,"lon":26.72509}},{"facility":"ARTES Psykiatrinen Palvelukeskus Oy","city":"Helsinki","zip":"00100","country":"Finland","geoPoint":{"lat":60.16952,"lon":24.93545}},{"facility":"Satucon Oy","city":"Kuopio","zip":"70100","country":"Finland","geoPoint":{"lat":62.89238,"lon":27.67703}},{"facility":"Satakunnan Psykiatripalveiu Oy at Mentoria Oy","city":"Tampere","zip":"26200","country":"Finland","geoPoint":{"lat":61.49911,"lon":23.78712}},{"facility":"Puutorin Psykiatripalvelu","city":"Turku","zip":"20100","country":"Finland","geoPoint":{"lat":60.45148,"lon":22.26869}},{"facility":"Gemeinschafstpraxis für Neurologie und Psychiatrie, Psychotherapie","city":"Achim","zip":"28832","country":"Germany","geoPoint":{"lat":53.01416,"lon":9.0263}},{"facility":"Private Praxis Dr. Jana Thomsen","city":"Berlin","zip":"10245","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"emovis GmbH","city":"Berlin","zip":"10629","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Alexander Schulze, MD","city":"Berlin","zip":"13156","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Private Practice Drs. Bitter/Schumann","city":"Bochum","zip":"44805","country":"Germany","geoPoint":{"lat":51.48165,"lon":7.21648}},{"facility":"University Hospital Carl Gustav Carus","city":"Dresden","zip":"01307","country":"Germany","geoPoint":{"lat":51.05089,"lon":13.73832}},{"facility":"ZSL Zentrum fuer medizinische Studien in Leipzig","city":"Leipzig","zip":"04157","country":"Germany","geoPoint":{"lat":51.33962,"lon":12.37129}},{"facility":"Studienzentrum Muenchen","city":"München","zip":"80333","country":"Germany","geoPoint":{"lat":51.60698,"lon":13.31243}},{"facility":"Universitaetsklinikum Munster","city":"Münster","zip":"48149","country":"Germany","geoPoint":{"lat":51.96236,"lon":7.62571}},{"facility":"Studienzentrum Klinikum Nuernberg","city":"Nuremberg","zip":"90419","country":"Germany","geoPoint":{"lat":49.45421,"lon":11.07752}},{"facility":"Somni bene GmbH","city":"Schwerin","zip":"19053","country":"Germany","geoPoint":{"lat":53.62937,"lon":11.41316}},{"facility":"Private Practice: Eugen Schlegel","city":"Siegen","zip":"57072","country":"Germany","geoPoint":{"lat":50.87481,"lon":8.02431}},{"facility":"Studiezentrum Nord-West","city":"Westerstede","zip":"26655","country":"Germany","geoPoint":{"lat":53.25682,"lon":7.92737}},{"facility":"Medizinisches Studienzentrum Wuerzburg","city":"Würzburg","zip":"97070","country":"Germany","geoPoint":{"lat":49.79391,"lon":9.95121}},{"facility":"Semmelweis Univ. Dept.of Psychiatry","city":"Budapest","zip":"1083","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Debrecent Egyetem Orvos es Egeszsegtudomanyl Centrum Pszichiatrai","city":"Debrecen","zip":"H-4032","country":"Hungary","geoPoint":{"lat":47.53167,"lon":21.62444}},{"facility":"Santha Kalman Mentalis Egeszsegkozpont es Szakkorhaz","city":"Nagykálló","zip":"4320","country":"Hungary","geoPoint":{"lat":47.87491,"lon":21.84082}},{"facility":"Josa Andras Teaching Hospital","city":"Nyíregyháza","zip":"H-4400","country":"Hungary","geoPoint":{"lat":47.95539,"lon":21.71671}},{"facility":"Pecsi Tudomanyegyeiem Pszichiatriai es Pszichoterapias Klinika","city":"Sziget","country":"Hungary","geoPoint":{"lat":47.91667,"lon":22.51667}},{"facility":"Prywatne Gabinety Lekarskie \"Promedicus\"","city":"Bialystok","zip":"15-879","country":"Poland","geoPoint":{"lat":53.13333,"lon":23.16433}},{"facility":"NZOZ Centrum Kultury, Higieny i Zdrowia Psychicznego","city":"Bydgoszcz","zip":"85-156","country":"Poland","geoPoint":{"lat":53.1235,"lon":18.00762}},{"facility":"Zespol Opieki Zdrowotnej w Chelmnie","city":"Chełmno","zip":"86-200","country":"Poland","geoPoint":{"lat":53.34855,"lon":18.4251}},{"facility":"Centrum Badan Klinicznuch Pl-House sp. z.o.o.","city":"Gdansk","zip":"80-546","country":"Poland","geoPoint":{"lat":54.35227,"lon":18.64912}},{"facility":"Klinika Chorob Psychicznych i Zaburzen Nerwicowych","city":"Gdansk","zip":"80-952","country":"Poland","geoPoint":{"lat":54.35227,"lon":18.64912}},{"facility":"Centrum Psychiatrii i Psychoterapli","city":"Gorlice","zip":"38-300","country":"Poland","geoPoint":{"lat":49.65563,"lon":21.16035}},{"facility":"NZOZ Syntonia, Poradnia Zdrowia Psychicznego","city":"Kielce","zip":"25-317","country":"Poland","geoPoint":{"lat":50.87033,"lon":20.62752}},{"facility":"Osrodek Badafi Klinicznych Prof dr hab n med Meszek Szczepanski Prywatna Praktyka Lekarska","city":"Lublin","zip":"20-022","country":"Poland","geoPoint":{"lat":51.25058,"lon":22.57009}},{"facility":"Samodzielny Publiczny Zespol Zakladow Opieki Zdrowotnej w Zurominie","city":"Żuromin","zip":"09-300","country":"Poland","geoPoint":{"lat":53.06611,"lon":19.90894}},{"facility":"Spitatul Clinic Judetean de Urgenta Arad, Clinica de Psihiatrie","city":"Arad","zip":"310022","country":"Romania","geoPoint":{"lat":46.18333,"lon":21.31667}},{"facility":"Stefi-Dent SRL","city":"Botoșani","zip":"710107","country":"Romania","geoPoint":{"lat":47.75,"lon":26.66667}},{"facility":"Spitalui Clinic de Psihiatrie \"Prof. Dr. Alexandru Obregia\" Sectia Clinica Psihiatrie I","city":"Bucharest","zip":"041915","country":"Romania","geoPoint":{"lat":44.43225,"lon":26.10626}},{"facility":"Crucea Alba","city":"Oradea","zip":"410163","country":"Romania","geoPoint":{"lat":47.0458,"lon":21.91833}},{"facility":"Lorentina 2201 SRL","city":"Targoviste","zip":"130081","country":"Romania","geoPoint":{"lat":44.92543,"lon":25.4567}},{"facility":"Spitalul Clinic Judetean Mures","city":"Târgu Mureş","zip":"540095","country":"Romania","geoPoint":{"lat":46.54245,"lon":24.55747}},{"facility":"Cape Trial Centre","city":"Bellville","state":"Cape Town","zip":"7530","country":"South Africa","geoPoint":{"lat":-33.90022,"lon":18.62847}},{"facility":"Flexivest Fourteen Research Centre","city":"Bellville","state":"Cape Town","zip":"7530","country":"South Africa","geoPoint":{"lat":-33.90022,"lon":18.62847}},{"facility":"Private Practice - Gerta Brink","city":"Johannesburg","state":"Gauten","zip":"2195","country":"South Africa","geoPoint":{"lat":-26.20227,"lon":28.04363}},{"facility":"Somerset West Clinical Research","city":"Somerset West","state":"Western Cape","country":"South Africa","geoPoint":{"lat":-34.08401,"lon":18.82113}},{"facility":"Vista Clinic","city":"Centurion","zip":"0046","country":"South Africa","geoPoint":{"lat":-25.85891,"lon":28.18577}},{"facility":"George Medi Clinic Extension","city":"George","zip":"6529","country":"South Africa","geoPoint":{"lat":-33.963,"lon":22.46173}},{"facility":"SU/ Affektiva 1","city":"Gothenburg","zip":"41685","country":"Sweden","geoPoint":{"lat":57.70716,"lon":11.96679}},{"facility":"ProbarE i Lund AB","city":"Lund","zip":"22222","country":"Sweden","geoPoint":{"lat":55.70584,"lon":13.19321}},{"facility":"Ekdahl Medical AB","city":"Malmö","zip":"21153","country":"Sweden","geoPoint":{"lat":55.60587,"lon":13.00073}},{"facility":"INM Psykiatrisk Mottagning","city":"Malmö","zip":"21153","country":"Sweden","geoPoint":{"lat":55.60587,"lon":13.00073}},{"facility":"Medinstructor Lippitz AB","city":"Stockholm","zip":"11486","country":"Sweden","geoPoint":{"lat":59.32938,"lon":18.06871}},{"facility":"Dr. Wahlstedts mottagning","city":"Uppsala","zip":"75310","country":"Sweden","geoPoint":{"lat":59.85882,"lon":17.63889}}]},"referencesModule":{"references":[{"pmid":"27474961","type":"RESULT","citation":"Richards C, McIntyre RS, Weisler R, Sambunaris A, Brawman-Mintzer O, Gao J, Geibel B, Dauphin M, Madhoo M. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies. J Affect Disord. 2016 Dec;206:151-160. doi: 10.1016/j.jad.2016.07.006. Epub 2016 Jul 5."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Antidepressant + Single-blind Placebo","description":"Subjects received unblinded oral, once daily standard antidepressant therapy (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) plus oral, once daily placebo (matching SPD489)."},{"id":"FG001","title":"Antidepressant + Double-blind SPD489","description":"Subjects received assigned oral, once daily antidepressant therapy (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride), plus oral, once daily SPD489 (Lisdexamfetamine dimesylate optimized among a 20, 30, 50, or 70 mg dose)."},{"id":"FG002","title":"Antidepressant + Double-blind Placebo","description":"Subjects received assigned oral, once daily antidepressant therapy (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) plus oral, once daily, double-blind placebo (matching SPD489)."}],"periods":[{"title":"Single-blind Lead-in Phase","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"Ten subjects were enrolled but not dosed.","numSubjects":"1105"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"823"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"282"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"26"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"24"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"69"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"43"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Met BP or Pulse Withdrawal Criteria","reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"107"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]}]},{"title":"Randomized Phase","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"These subjects were not included in the Safety Analysis Set or Full Analysis Set.","numSubjects":"397"},{"groupId":"FG001","comment":"One subject was randomized to this arm but did not receive at least 1 dose of double-blind treatment","numSubjects":"212"},{"groupId":"FG002","comment":"One subject was randomized to this arm but did not receive at least 1 dose of double-blind treatment","numSubjects":"214"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"353"},{"groupId":"FG001","numSubjects":"181"},{"groupId":"FG002","numSubjects":"189"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"44"},{"groupId":"FG001","numSubjects":"31"},{"groupId":"FG002","numSubjects":"25"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"6"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"2"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"9"},{"groupId":"FG002","numSubjects":"8"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"4"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Met BP Or Pulse Withdrawal Criteria","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"4"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Safety Analysis Set: All subjects who took at least 1 dose of randomized investigational product and who had at least 1 safety assessment.","groups":[{"id":"BG000","title":"Antidepressant + Double-blind SPD489","description":"Subjects received assigned oral, once daily antidepressant therapy (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride), plus oral, once daily SPD489 (Lisdexamfetamine dimesylate optimized among a 20, 30, 50, or 70 mg dose) for 8 weeks."},{"id":"BG001","title":"Antidepressant + Double-blind Placebo","description":"Subjects received assigned oral, once daily antidepressant therapy (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) plus oral, once daily, double-blind placebo (matching SPD489) for 8 weeks."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"211"},{"groupId":"BG001","value":"213"},{"groupId":"BG002","value":"424"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"42","spread":"11.63"},{"groupId":"BG001","value":"42.6","spread":"11.41"},{"groupId":"BG002","value":"42.3","spread":"11.51"}]}]}]},{"title":"Age, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"18-55 years","categories":[{"measurements":[{"groupId":"BG000","value":"181"},{"groupId":"BG001","value":"184"},{"groupId":"BG002","value":"365"}]}]},{"title":"56-65 years","categories":[{"measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"59"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"141"},{"groupId":"BG001","value":"143"},{"groupId":"BG002","value":"284"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"70"},{"groupId":"BG001","value":"70"},{"groupId":"BG002","value":"140"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at 8 Weeks","description":"MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.","populationDescription":"Full Analysis Set: Subjects who took at least 1 dose of randomized investigational product and who had at least 1 valid primary efficacy measurement of the MADRS total score after the Augmentation Baseline Visit (Visit 8).","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"units on a scale","timeFrame":"8 weeks","groups":[{"id":"OG000","title":"Antidepressant + SPD489","description":"Antidepressant + SPD489 (Lisdexamfetamine dimesylate): Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + SPD489 (optimized as a 20, 30, 50, or 70 mg dose, oral, once daily), for 8 weeks."},{"id":"OG001","title":"Antidepressant + Placebo","description":"Antidepressant + Placebo: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"213"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.3","lowerLimit":"-8.6","upperLimit":"-6.0"},{"groupId":"OG001","value":"-6.8","lowerLimit":"-8.1","upperLimit":"-5.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.583","statisticalMethod":"Mixed-effects Model for Repeat Measures","paramType":"Mean Difference (Final Values)","paramValue":"-0.5","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.3","ciUpperLimit":"1.3","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.92"}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Sheehan Disability Scale (SDS) Total Score at 8 Weeks","description":"Designed to evaluate the extent to which illness symptoms impact a subject's life in 3 areas: work/school, social, and family/home. Each area is scored on a scale from 0 (no impairment) to 10 (highly impaired) with a total score ranging from 0 (unimpaired) to 30 (highly impaired). Lower scores translate into less impairment.","populationDescription":"Full Analysis Set: Subjects who took at least 1 dose of randomized investigational product and who had at least 1 valid primary efficacy measurement of the MADRS total score after the Augmentation Baseline Visit (Visit 8).","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"units on a scale","timeFrame":"8 weeks","groups":[{"id":"OG000","title":"Antidepressant + SPD489","description":"Antidepressant + SPD489 (Lisdexamfetamine dimesylate): Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + SPD489 (optimized as a 20, 30, 50, or 70 mg dose, oral, once daily), for 8 weeks."},{"id":"OG001","title":"Antidepressant + Placebo","description":"Antidepressant + Placebo: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"213"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.9","lowerLimit":"-5.8","upperLimit":"-4.0"},{"groupId":"OG001","value":"-4.3","lowerLimit":"-5.2","upperLimit":"-3.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.354","statisticalMethod":"Mixed-effects Model for Repeat Measures","paramType":"Mean Difference (Final Values)","paramValue":"-0.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.9","ciUpperLimit":"0.7","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.65"}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a 25% Response on the MADRS","description":"The percentage of subjects who achieved a 25% response (i.e. ≥25% reduction in MADRS total score from the Lead-in Baseline, Visit 2).","populationDescription":"Full Analysis Set: Subjects who took at least 1 dose of randomized investigational product and who had at least 1 valid primary efficacy measurement of the MADRS total score after the Augmentation Baseline Visit (Visit 8).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Up to 8 weeks","groups":[{"id":"OG000","title":"Antidepressant + SPD489","description":"Antidepressant + SPD489 (Lisdexamfetamine dimesylate): Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + SPD489 (optimized as a 20, 30, 50, or 70 mg dose, oral, once daily), for 8 weeks."},{"id":"OG001","title":"Antidepressant + Placebo","description":"Antidepressant + Placebo: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"213"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.9"},{"groupId":"OG001","value":"74.2"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a 50% Response on the MADRS","description":"The percentage of subjects who achieved a 50% response (i.e. ≥50% reduction in MADRS total score from the Lead-in Baseline, Visit 2).","populationDescription":"Full Analysis Set: Subjects who took at least 1 dose of randomized investigational product and who had at least 1 valid primary efficacy measurement of the MADRS total score after the Augmentation Baseline Visit (Visit 8).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Up to 8 weeks","groups":[{"id":"OG000","title":"Antidepressant + SPD489","description":"Antidepressant + SPD489 (Lisdexamfetamine dimesylate): Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + SPD489 (optimized as a 20, 30, 50, or 70 mg dose, oral, once daily), for 8 weeks."},{"id":"OG001","title":"Antidepressant + Placebo","description":"Antidepressant + Placebo: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"213"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.6"},{"groupId":"OG001","value":"37.1"}]}]}]},{"type":"SECONDARY","title":"Percent of Participants Achieving Remission on the MADRS","description":"MADRS remission was defined as a MADRS total score of ≤10.","populationDescription":"Full Analysis Set: Subjects who took at least 1 dose of randomized investigational product and who had at least 1 valid primary efficacy measurement of the MADRS total score after the Augmentation Baseline Visit (Visit 8).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Up to 8 weeks","groups":[{"id":"OG000","title":"Antidepressant + SPD489","description":"Antidepressant + SPD489 (Lisdexamfetamine dimesylate): Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + SPD489 (optimized as a 20, 30, 50, or 70 mg dose, oral, once daily), for 8 weeks."},{"id":"OG001","title":"Antidepressant + Placebo","description":"Antidepressant + Placebo: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"213"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.0"},{"groupId":"OG001","value":"17.8"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline Over Time in MADRS Total Score","description":"MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.","populationDescription":"Full Analysis Set: Subjects who took at least 1 dose of randomized investigational product and who had at least 1 valid primary efficacy measurement of MADRS total score after the Augmentation Baseline Visit (Visit 8). Sample size (n) of MADRS total score at each visit differed from sample size (N) of the FAS.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"units on a scale","timeFrame":"Up to 8 weeks","groups":[{"id":"OG000","title":"Antidepressant + SPD489","description":"Antidepressant + SPD489 (Lisdexamfetamine dimesylate): Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + SPD489 (optimized as a 20, 30, 50, or 70 mg dose, oral, once daily), for 8 weeks."},{"id":"OG001","title":"Antidepressant + Placebo","description":"Antidepressant + Placebo: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"213"}]}],"classes":[{"title":"Week 9 (Visit 9)","categories":[{"measurements":[{"groupId":"OG000","value":"-2.9","lowerLimit":"-3.9","upperLimit":"-2.0"},{"groupId":"OG001","value":"-2.1","lowerLimit":"-3.0","upperLimit":"-1.1"}]}]},{"title":"Week 10 (Visit 10)","categories":[{"measurements":[{"groupId":"OG000","value":"-4.4","lowerLimit":"-5.5","upperLimit":"-3.3"},{"groupId":"OG001","value":"-4.3","lowerLimit":"-5.4","upperLimit":"-3.2"}]}]},{"title":"Week 11 (Visit 11)","categories":[{"measurements":[{"groupId":"OG000","value":"-5.9","lowerLimit":"-7.1","upperLimit":"-4.7"},{"groupId":"OG001","value":"-5.0","lowerLimit":"-6.2","upperLimit":"-3.8"}]}]},{"title":"Week 12 (Visit 12)","categories":[{"measurements":[{"groupId":"OG000","value":"-6.3","lowerLimit":"-7.6","upperLimit":"-5.1"},{"groupId":"OG001","value":"-5.3","lowerLimit":"-6.5","upperLimit":"-4.1"}]}]},{"title":"Week 14 (Visit 13)","categories":[{"measurements":[{"groupId":"OG000","value":"-6.9","lowerLimit":"-8.2","upperLimit":"-5.5"},{"groupId":"OG001","value":"-6.4","lowerLimit":"-7.7","upperLimit":"-5.1"}]}]},{"title":"Week 16 (Visit 14)","categories":[{"measurements":[{"groupId":"OG000","value":"-7.3","lowerLimit":"-8.6","upperLimit":"-6.0"},{"groupId":"OG001","value":"-6.8","lowerLimit":"-8.1","upperLimit":"-5.5"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Abbreviated Brief Assessment of Cognition Affective Disorders (ABAC-A) Composite T-Scores","description":"The ABAC-A is a rater-administered series of activities designed to be sensitive to the critical cognitive deficits in affective disorders and schizophrenia. There are 6 subtests of the ABAC-A: List Learning (verbal memory); Digit Sequencing Task (working memory); Token Motor Task (motor speed); Verbal Fluency; Symbol Coding (attention and processing speed); and Tower of London Test (executive functions). The ABAC-A Composite T-score change from Augmentation Baseline Visit (Visit 8; Week 8) at Visit 14/Early Termination (ET) (Week 16/ET) was analyzed.","populationDescription":"Full Analysis Set: Subjects who took at least 1 dose of randomized investigational product and who had at least 1 valid primary efficacy measurement of the MADRS total score after the Augmentation Baseline Visit (Visit 8).","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"t-score","timeFrame":"up to 8 weeks","groups":[{"id":"OG000","title":"Antidepressant + SPD489","description":"Antidepressant + SPD489 (Lisdexamfetamine dimesylate): Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + SPD489 (optimized as a 20, 30, 50, or 70 mg dose, oral, once daily), for 8 weeks."},{"id":"OG001","title":"Antidepressant + Placebo","description":"Antidepressant + Placebo: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"198"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","lowerLimit":"2.1","upperLimit":"4.0"},{"groupId":"OG001","value":"2.5","lowerLimit":"1.5","upperLimit":"3.5"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in the Short Form-12 Health Survey V2 (SF-12V2)","description":"Total score ranges from 0 (lowest level of health) - 100 (highest level of health) on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability (i.e. a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability). Higher scores are associated with better quality of life.","populationDescription":"Full Analysis Set: Subjects who took at least 1 dose of randomized investigational product and who had at least 1 valid primary efficacy measurement of the MADRS total score after the Augmentation Baseline Visit (Visit 8).","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"units on a scale","timeFrame":"Up to 8 weeks","groups":[{"id":"OG000","title":"Antidepressant + SPD489","description":"Antidepressant + SPD489 (Lisdexamfetamine dimesylate): Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + SPD489 (optimized as a 20, 30, 50, or 70 mg dose, oral, once daily), for 8 weeks."},{"id":"OG001","title":"Antidepressant + Placebo","description":"Antidepressant + Placebo: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"205"}]}],"classes":[{"title":"Physical","categories":[{"measurements":[{"groupId":"OG000","value":"1.07","lowerLimit":"0.04","upperLimit":"2.10"},{"groupId":"OG001","value":"0.90","lowerLimit":"-0.11","upperLimit":"1.91"}]}]},{"title":"Mental","categories":[{"measurements":[{"groupId":"OG000","value":"6.63","lowerLimit":"5.03","upperLimit":"8.23"},{"groupId":"OG001","value":"5.16","lowerLimit":"3.60","upperLimit":"6.73"}]}]}]},{"type":"SECONDARY","title":"Mean Change in Sexual Functioning Questionnaire - 14 Item Scale (CSFQ-14) Total Score Male","description":"The CSFQ-14 is a short-form interview/questionnaire that measures illness- and medication-related changes in sexual functioning. A 5-point Likert scale is used ranging from 1 (never) to 5 (always). The CSFQ-14 total score can range from 14 to 70, with lower scores being associated with worsened sexual functioning.","populationDescription":"Full Analysis Set: Male subjects who took at least 1 dose of randomized investigational product and who had at least 1 valid primary efficacy measurement of the MADRS total score after the Augmentation Baseline Visit (Visit 8).","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Up to 8 weeks","groups":[{"id":"OG000","title":"Antidepressant + SPD489","description":"Antidepressant + SPD489 (Lisdexamfetamine dimesylate): Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + SPD489 (optimized as a 20, 30, 50, or 70 mg dose, oral, once daily), for 8 weeks."},{"id":"OG001","title":"Antidepressant + Placebo","description":"Antidepressant + Placebo: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"6.22"},{"groupId":"OG001","value":"1.0","spread":"6.02"}]}]}]},{"type":"SECONDARY","title":"Mean Change in Sexual Functioning Questionnaire - 14 Item Scale (CSFQ-14) Total Score Female","description":"The CSFQ-14 is a short-form interview/questionnaire that measures illness- and medication-related changes in sexual functioning. A 5-point Likert scale is used ranging from 1 (never) to 5 (always). The CSFQ-14 total score can range from 14 to 70, with lower scores being associated with worsened sexual functioning.","populationDescription":"Full Analysis Set: Female subjects who took at least 1 dose of randomized investigational product and who had at least 1 valid primary efficacy measurement of the MADRS total score after the Augmentation Baseline Visit (Visit 8).","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Up to 8 weeks","groups":[{"id":"OG000","title":"Antidepressant + SPD489","description":"Antidepressant + SPD489 (Lisdexamfetamine dimesylate): Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + SPD489 (optimized as a 20, 30, 50, or 70 mg dose, oral, once daily), for 8 weeks."},{"id":"OG001","title":"Antidepressant + Placebo","description":"Antidepressant + Placebo: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"133"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":"7.11"},{"groupId":"OG001","value":"1.9","spread":"5.82"}]}]}]},{"type":"SECONDARY","title":"Clinical Global Impressions - Global Improvement (CGI-I)","description":"Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.","populationDescription":"Full Analysis Set: Subjects who took at least 1 dose of randomized investigational product and who had at least 1 valid primary efficacy measurement of the MADRS total score after the Augmentation Baseline Visit (Visit 8).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Up to 8 weeks","groups":[{"id":"OG000","title":"Antidepressant + SPD489","description":"Antidepressant + SPD489 (Lisdexamfetamine dimesylate): Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + SPD489 (optimized as a 20, 30, 50, or 70 mg dose, oral, once daily), for 8 weeks."},{"id":"OG001","title":"Antidepressant + Placebo","description":"Antidepressant + Placebo: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"213"}]}],"classes":[{"title":"Improved","categories":[{"measurements":[{"groupId":"OG000","value":"56.9"},{"groupId":"OG001","value":"53.5"}]}]},{"title":"Not Improved","categories":[{"measurements":[{"groupId":"OG000","value":"43.1"},{"groupId":"OG001","value":"46.5"}]}]},{"title":"Not Assessed","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in the Multidimensional Assessment of Fatigue (MAF) Global Fatigue Index (GFI)","description":"MAF contains 16 items scored on a scale from 1 (not at all) to 10 (a great deal). Answers are converted to a Global Fatigue Index with total scores ranging from 1 (no fatigue) to 50 (severe fatigue). Lower scores indicate less fatigue.","populationDescription":"Full Analysis Set: Subjects who took at least 1 dose of randomized investigational product and who had at least 1 valid primary efficacy measurement of the MADRS total score after the Augmentation Baseline Visit (Visit 8).","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Up to 8 weeks","groups":[{"id":"OG000","title":"Antidepressant + SPD489","description":"Antidepressant + SPD489 (Lisdexamfetamine dimesylate): Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + SPD489 (optimized as a 20, 30, 50, or 70 mg dose, oral, once daily), for 8 weeks."},{"id":"OG001","title":"Antidepressant + Placebo","description":"Antidepressant + Placebo: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"205"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.6","spread":"0.74"},{"groupId":"OG001","value":"-4.4","spread":"0.73"}]}]}]},{"type":"SECONDARY","title":"Columbia Suicide Severity Rating Scale (C-SSRS)","description":"C-SSRS is a semi-structured interview that captures the occurence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale.","populationDescription":"Safety Analysis Set: All subjects who took at least 1 dose of randomized investigational product and who had at least 1 safety assessment (e.g., coming back for any visit, reporting of an adverse event \\[AE\\], or reporting the absence of AEs) after the Augmentation Baseline Visit (Visit 8).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Up to 8 weeks","groups":[{"id":"OG000","title":"Antidepressant + SPD489","description":"Antidepressant + SPD489 (Lisdexamfetamine dimesylate): Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + SPD489 (optimized as a 20, 30, 50, or 70 mg dose, oral, once daily), for 8 weeks."},{"id":"OG001","title":"Antidepressant + Placebo","description":"Antidepressant + Placebo: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"211"},{"groupId":"OG001","value":"213"}]}],"classes":[{"title":"≥1 positive suicidal ideation","categories":[{"measurements":[{"groupId":"OG000","value":"9.0"},{"groupId":"OG001","value":"9.4"}]}]},{"title":"≥1 suicidal attempt","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0.5"}]}]}]},{"type":"SECONDARY","title":"Amphetamine Cessation Symptom Assessment (ACSA) - Total Aggregate Score","description":"ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity.","populationDescription":"Safety Analysis Set: All subjects who took at least 1 dose of randomized investigational product and who had at least 1 safety assessment (e.g., coming back for any visit, reporting of an AE, or reporting the absence of AEs) after the Augmentation Baseline Visit (Visit 8).","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Score","timeFrame":"8 weeks","groups":[{"id":"OG000","title":"Antidepressant + SPD489","description":"Antidepressant + SPD489 (Lisdexamfetamine dimesylate): Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + SPD489 (optimized as a 20, 30, 50, or 70 mg dose, oral, once daily), for 8 weeks."},{"id":"OG001","title":"Antidepressant + Placebo","description":"Antidepressant + Placebo: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"199"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.0","spread":"10.80"},{"groupId":"OG001","value":"17.2","spread":"10.56"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"SPD489","description":"Antidepressant + SPD489 (Lisdexamfetamine dimesylate ): Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + SPD489 (oral, 20, 30, 50 or 70 mg, once daily) for 8 weeks","seriousNumAffected":1,"seriousNumAtRisk":211,"otherNumAffected":72,"otherNumAtRisk":211},{"id":"EG001","title":"Placebo","description":"Antidepressant + Placebo: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks","seriousNumAffected":1,"seriousNumAtRisk":213,"otherNumAffected":46,"otherNumAtRisk":213}],"seriousEvents":[{"term":"Suicidal ideation","organSystem":"Psychiatric disorders","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":211},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":213}]},{"term":"Accelerated hypertension","organSystem":"Vascular disorders","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":211},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":213}]}],"otherEvents":[{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numEvents":29,"numAffected":25,"numAtRisk":211},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":213}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":211},{"groupId":"EG001","numEvents":20,"numAffected":19,"numAtRisk":213}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","stats":[{"groupId":"EG000","numEvents":14,"numAffected":13,"numAtRisk":211},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":213}]},{"term":"Headache","organSystem":"Nervous system disorders","stats":[{"groupId":"EG000","numEvents":32,"numAffected":25,"numAtRisk":211},{"groupId":"EG001","numEvents":22,"numAffected":16,"numAtRisk":213}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","stats":[{"groupId":"EG000","numEvents":14,"numAffected":11,"numAtRisk":211},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":213}]},{"term":"Hyperhidrosis","organSystem":"Skin and subcutaneous tissue disorders","stats":[{"groupId":"EG000","numEvents":16,"numAffected":11,"numAtRisk":211},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":213}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually."},"pointOfContact":{"title":"Study Director","organization":"Shire","email":"ClinicalTransparency@shire.com","phone":"+1 866 842 5335"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-13"},"conditionBrowseModule":{"meshes":[{"id":"D003865","term":"Depressive Disorder, Major"}],"ancestors":[{"id":"D003866","term":"Depressive Disorder"},{"id":"D019964","term":"Mood Disorders"},{"id":"D001523","term":"Mental Disorders"}]},"interventionBrowseModule":{"meshes":[{"id":"D000928","term":"Antidepressive Agents"},{"id":"D000069478","term":"Lisdexamfetamine Dimesylate"}],"ancestors":[{"id":"D011619","term":"Psychotropic Drugs"},{"id":"D002491","term":"Central Nervous System Agents"},{"id":"D045506","term":"Therapeutic Uses"},{"id":"D020228","term":"Pharmacologic Actions"},{"id":"D020164","term":"Chemical Actions and Uses"},{"id":"D003913","term":"Dextroamphetamine"},{"id":"D000661","term":"Amphetamine"},{"id":"D000662","term":"Amphetamines"},{"id":"D010627","term":"Phenethylamines"},{"id":"D005021","term":"Ethylamines"},{"id":"D000588","term":"Amines"},{"id":"D009930","term":"Organic Chemicals"}]}},"hasResults":true}